Form 4: BioCryst Pharmaceuticals Chief Legal Officer Reports Stock Transaction
SEC Form 4 Filing
Alane P. Barnes, Chief Legal Officer of BioCryst Pharmaceuticals, had shares withheld to cover tax obligations related to vesting restricted stock units.
Summary
- Alane P. Barnes, the Chief Legal Officer of BioCryst Pharmaceuticals, filed a Form 4 indicating a transaction involving the company's stock.
- On December 14, 2024, 8,613 shares of common stock were withheld by the issuer to satisfy tax obligations related to the vesting of restricted stock units.
- This transaction did not represent a sale by Ms. Barnes, but rather a transfer of shares to cover taxes.
- Following the transaction, Ms. Barnes beneficially owns 294,490 shares of BioCryst Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing and does not indicate any positive or negative sentiment. It is a neutral transaction related to tax obligations.
Industry Context
Form 4 filings are a routine part of regulatory compliance for publicly traded companies, providing transparency into the transactions of company insiders. This filing is a standard disclosure and does not indicate any unusual activity.
Comparison to Industry Standards
- Form 4 filings are a standard practice for all publicly traded companies in the US, as mandated by the SEC.
- The transaction is typical of how companies handle tax obligations related to vesting of restricted stock units for employees and executives.
- Similar filings can be seen across the pharmaceutical industry for companies such as Gilead Sciences (GILD) and Amgen (AMGN) when their executives have similar transactions.
Stakeholder Impact
- The transaction has a neutral impact on shareholders as it is a standard procedure for tax obligations.
- The transaction does not impact employees, customers, suppliers or creditors.
Key Dates
| Date | Description |
|---|---|
| 12/14/2024 | Date of the stock transaction where shares were withheld for tax obligations. |
| 12/17/2024 | Date the Form 4 was signed by Alane P. Barnes. |
Keywords
Form 4, BioCryst Pharmaceuticals, BCRX, insider trading, stock transaction, restricted stock units, tax withholding, Alane P. Barnes, Chief Legal Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.